Scientists combine tumor-targeting peptides and nanoparticles to destroy glioblastoma

Oct 03, 2011

Glioblastoma is one of the most aggressive forms of brain cancer. Rather than presenting as a well-defined tumor, glioblastoma will often infiltrate the surrounding brain tissue, making it extremely difficult to treat surgically or with chemotherapy or radiation. Likewise, several mouse models of glioblastoma have proven completely resistant to all treatment attempts.

In a new study, a team led by scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and the Salk Institute for Biological Studies developed a method to combine a tumor-homing peptide, a cell-killing peptide, and a nanoparticle that both enhances and allows the researchers to image the tumors. When used to treat mice with glioblastoma, this new nanosystem eradicated most tumors in one model and significantly delayed in another. These findings were published the week of October 3 in the .

"This is a unique nanosystem for two reasons. First, linking the cell-killing peptide to nanoparticles made it possible for us to deliver it specifically to tumors, virtually eliminating the killer peptide's toxicity to normal tissues. Second, ordinarily researchers and clinicians are happy if they are able to deliver more drugs to a tumor than to normal tissues. We not only accomplished that, but were able to design our nanoparticles to deliver the killer peptide right where it acts—the mitochondria, the cell's energy-generating center," said Erkki Ruoslahti, M.D., Ph.D., senior author of the study and distinguished professor in both Sanford-Burnham's NCI-designated Cancer Center in La Jolla and the Center for Nanomedicine, a Sanford-Burnham collaboration with the University of California, Santa Barbara.

The nanosystem developed in this study is made up of three elements. First, a nanoparticle acts as the carrier framework for an imaging agent and for two peptides (short proteins). One of these peptides guides the nanoparticle and its payload specifically to cancer cells and the blood vessels that feed them by binding cell surface markers that distinguish them from normal cells. This same peptide also drives the whole system inside these target cells, where the second peptide wreaks havoc on the mitochondria, triggering cellular suicide through a process known as apoptosis.

Together, these and nanoparticles proved extremely effective at treating two different mouse models of glioblastoma. In the first model, treated mice survived significantly longer than untreated mice. In the second model, untreated mice survived for only eight to nine weeks. In sharp contrast, treatment with this nanosystem cured all but one of ten mice. What's more, in addition to providing therapy, the nanoparticles could aid in diagnosing glioblastoma; they are made of iron oxide, which makes them—and therefore the tumors they target—visible by MRI, the same technique already used to diagnose many health conditions.

In a final twist, the researchers made the whole nanosystem even more effective by administering it to the mice in conjunction with a third peptide. Dr. Ruoslahti and his team previously showed that this peptide, known as iRGD, helps co-administered drugs penetrate deeply into tumor tissue. iRGD has been shown to substantially increase treatment efficacy of various drugs against human breast, prostate, and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug. Here, iRGD enhanced nanoparticle penetration and therapeutic efficacy.

"In this study, our patients were mice that developed glioblastomas with the same characteristics as observed in humans with the disease. We treated them systemically with the nanoparticles. Once the reached the tumors' blood vessels, they delivered their payload (a drug) directly to the cell's power producer, the mitochondria. By destroying the blood vessels and also some surrounding , we were able to cure some mice and extend the lifespan of the rest," said Dinorah Friedmann-Morvinski, Ph.D., co-first author of the study and post-doctoral research associate in the laboratory of Inder Verma, Ph.D. at the Salk Institute.

Explore further: Molecular beacons shine light on how cells 'crawl'

Provided by Sanford-Burnham Medical Research Institute

5 /5 (7 votes)

Related Stories

Delivering medicine directly into a tumor

Dec 07, 2009

Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal ...

Cancer drug effectiveness substantially advanced

Apr 08, 2010

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human ...

Therapeutic nanoparticles targeted to radiation treated tumors

Mar 28, 2011

Radiation and chemotherapy are common partners in anticancer therapy for solid tumors, but too often, the combined side effects associated with each mode of therapy can limit how aggressively oncologists can treat their patients. ...

Multifunctional Nanoparticles Image and Treat Brain Tumors

Dec 04, 2006

Combining two promising approaches to diagnosing and treating cancer, a multidisciplinary research team at the University of Michigan has created a targeted multifunctional polymer nanoparticle that successfully images and ...

Nanoparticles working in harmony

Jul 15, 2011

For decades, researchers have been working to develop nanoparticles that deliver cancer drugs directly to tumors, minimizing the toxic side effects of chemotherapy. However, even with the best of these nanoparticles, only ...

Recommended for you

Molecular beacons shine light on how cells 'crawl'

Oct 24, 2014

Adherent cells, the kind that form the architecture of all multi-cellular organisms, are mechanically engineered with precise forces that allow them to move around and stick to things. Proteins called integrin ...

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

Shakescene21
5 / 5 (1) Oct 03, 2011
I hope this goes straight to human trials without any delay. This terrible cancer is so aggressive and incurable that it is more humane to use this experimentally on people than to deny it to them and let them die hopelessly.
Birger
not rated yet Oct 04, 2011
They were able to "design [their] nanoparticles to deliver the killer peptide right where it actsthe mitochondria".

To get further synergetic effects, maybe they should combine it with other substances who work on the mitochondria. The University of Alberta has had some modest success with using dichloracetate (DCA) to trigger apoptosis through the effect on the mitochondria of cancer cells.
ABSOLUTEKNOWLEDGE
1 / 5 (1) Oct 04, 2011
I hope this goes straight to human trials without any delay. This terrible cancer is so aggressive and incurable that it is more humane to use this experimentally on people than to deny it to them and let them die hopelessly.


that would only hapen in a world where drug cartles dont run the show so they delay silence buy off and barie any real treatmnet or cure it would hurt there profits
ibtimmons
not rated yet Oct 04, 2011
Score another win for the mice, there sure are a bunch of cancer-free mice running around out there.